Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: david nordic who wrote (234)	6/5/2007 10:10:04 AM
From: tuck	Read Replies (4) \| Respond to of 507

Notable calls summarizes Soleil's buy reiteration: notablecalls.blogspot.com I see NKTR share price hasn't responded. I don't know what to make of the Cimzia situation. It seems as though there's been a fair amount of time gone by for mere label negotiations or submissions of new data, and there is a camp that believes the situation for Cimzia is more dire, that the FDA is asking for a trial before approval. The shriller members of that camp believe the one case of tuberculosis could be a stumbling block, both in the regulatory and marketing arenas. Even Mircera is slightly in doubt. A couple of analysts say that even though Roche was given a draft label, there is a slim chance that there are larger issues for it. I believe, though that the share is close to reflecting these concerns. I expect the market to consolidate this summer, and will be watching to go long NKTR again. Cheers, Tuck